Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 10Phase 1/2 4Phase 2/3 3Phase NA 1Phase 4 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Stomach Neoplasms 5Breast Neoplasms 5HER2-positive Breast Cancer 3Neoplasms 2Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoproliferative Disorders 1Lung Neoplasms 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 3pertuzumab 2Docetaxel 2tucatinib 1Protons 1Paclitaxel 1Carboplatin 1Capecitabine 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × HER2-positive Breast Cancer × Trastuzumab × Clear all
NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Unknown
190 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡